PA
PBYI icon

Parallel Advisors’s Puma Biotechnology PBYI Stock Holding History

Parallel Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$397 Buy
+49
New +$359 ﹤0.01% 3813

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors's PBYI Position: Q2 2026 in Review

Parallel Advisors opened a new position in Puma Biotechnology (PBYI) in Q2 2026: 49 shares worth $397. The stake represents ﹤0.01% of the portfolio and ranks #3813 among its holdings.

161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Parallel Advisors held 49 shares of Puma Biotechnology worth $397 as of Q2 2026.
  • Puma Biotechnology was a new Parallel Advisors position in Q2 2026.
  • Puma Biotechnology made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3813 holding.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.